Skip to main content
Clinical Trials/ISRCTN15677760
ISRCTN15677760RecruitingNot Applicable

An investigation of the therapeutic impact of intra-carotid arterial transfusion of autologous peripheral blood-derived stem cell/progenitor cell (CD34+) therapy on acute ischemic stroke --- a phase II randomized controlled clinical trial

Chang Gung Memorial Hospital0 sites116 target enrollmentStarted: April 23, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
116

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Suffer from acute ischemic stroke within 14 ± 7 days
  • 2. Evidence of brain ischemia on nuclear medicine examination
  • 3. NIHSS score between 8 and 21
  • 4. Already on standard medical therapy based upon stroke guideline, e.g., antiplatelet, antihypertensive, and statin.

Exclusion Criteria

  • 1. Age less than 45 years old or more than 80 years old
  • 2. Patients received t-PA and anticoagulation
  • 3. Non-middle cerebral artery territory stroke or hemorrhagic stroke
  • 4. Pregnant women
  • 5. Patients with active infectious disease or autoimmune disorder
  • 6. Myocardial infarction (MI) within 3 months
  • 7. Severe aortic stenosis or mitral stenosis
  • 8. Congestive heart failure, New York Heart Association functional class IV
  • 9. Malignancy or other severe disease with life span less than one year
  • 10. Chronic kidney disease with CCr<20ml/min and end stage renal disease
  • 11. Join other clinical trials
  • 12. Patients cannot receive regular follow-up
  • 13. Other brain disease (tumor, degenerative disease, infective disease)

Investigators

Sponsor
Chang Gung Memorial Hospital

Similar Trials